Table 1 Baseline characteristics of the global cohort
Characteristics | Total (N = 505) | |
|---|---|---|
Age (years) | Mean (standard deviation) | 64 (12.2) |
Sex | Male | 198 (39.2%) |
Female | 307 (60.8%) | |
ECOG * | 0 | 160 (31.8%) |
1 | 272 (54%) | |
2 | 55 (10.9%) | |
3 | 15 (3%) | |
4 | 2 (0.4%) | |
Weight loss * | Yes | 104 (27.2%) |
No | 278 (72.8%) | |
Smoking history * | Never smoker | 269 (54.0%) |
Ex-smoker | 168 (33.7%) | |
Current smoker | 61 (12.3%) | |
Lives with a smoker * | Yes | 43 (24.9%) |
No | 130 (75.1%) | |
Distribution of stages | Stage IIIB | 30 (5.9%) |
Stage IV | 475 (94.1%) | |
Histology | Adenocarcinoma | 482 (95.5%) |
Other | 23 (4.6%) | |
Type of mutation ** | Exon 19 deletion | 279 (55.2%) |
L858R | 143 (28.3%) | |
Exon 20 insertion | 24 (4.7%) | |
Exon 18 G719X | 17 (3.4%) | |
S768I | 10 (2%) | |
Unknown | 20 (4%) | |
L861Q | 2 (0.4%) | |
T790M at diagnosis | 22 (4.3%) | |
N° of metastatic sites | 0 | 30 (5.9%) |
1 | 182 (36.0%) | |
2 | 126 (25%) | |
3 | 85 (16.8%) | |
4 | 48 (9.5%) | |
5 | 23 (4.6%) | |
6 | 2 (0.4%) | |
7 | 3 (0.6%) | |
Unknown | 6 (1.2%) | |
N° of patients with metastatic site at diagnosis** | Bone | 208 (41.2%) |
Lung | 190 (37.6%) | |
Pleural effusion | 136 (26.9%) | |
CNS | 85 (16.8%) | |
Liver | 73 (14.5%) | |
Adrenal glands | 45 (8.9%) | |
Pericardial effusion | 11 (2.2%) |